Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cellular resistance to anthracyclines

D Nielsen1, C Maare, T Skovsgaard

  • 1Department of Oncology R, University of Copenhagen, Denmark.

General Pharmacology
|March 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiotherapy quality assurance of patients with squamous cell carcinoma of the head and neck included in the DAHANCA 19 randomised phase III trial.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

Considerations for study design in the DAHANCA 35 trial of protons versus photons for head and neck cancer.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2023
Same author

Genomic landscape of treatment refractory metastatic colorectal cancer.

Acta oncologica (Stockholm, Sweden)·2021
Same author

Exploring the patient perspectives of mobile X-ray in nursing homes - A qualitative explorative pilot study.

Radiography (London, England : 1995)·2020
Same author

PD-L1 diagnostics in the neoadjuvant setting: implications of intratumoral heterogeneity of PD-L1 expression in triple negative breast cancer for assessment in small biopsies.

Breast cancer research and treatment·2020
Same author

NTCP model validation method for DAHANCA patient selection of protons versus photons in head and neck cancer radiotherapy.

Acta oncologica (Stockholm, Sweden)·2019
Same journal

Endothelium-dependent vasorelaxant and antiproliferative effects of apigenin.

General pharmacology·2002
Same journal

Reversal of hypercapnia induces endothelin-dependent constriction of basilar artery in rabbits with acute metabolic alkalosis.

General pharmacology·2002
Same journal

Reversal of hypercapnia induces KATP channel and NO-independent constriction of basilar artery in rabbits with acute metabolic alkalosis.

General pharmacology·2002
Same journal

Contractile responses in spontaneously diabetic mice. II. Effect of cholestyramine on enhanced contractile response of aorta to norepinephrine in C57BL/KsJ (db/db) mice.

General pharmacology·2002
Same journal

Contractile responses in spontaneously diabetic mice. I. Involvement of superoxide anion in enhanced contractile response of aorta to norepinephrine in C57BL/KsJ(db/db) mice.

General pharmacology·2002
Same journal

Investigation of basal endothelial function in the obese Zucker rat in vitro.

General pharmacology·2002
See all related articles

Anthracyclines fight cancer by inhibiting topoisomerase II (TOPO II). Tumor cells develop resistance through various mechanisms, including drug pumps like P-glycoprotein (PGP), but only PGP-mediated resistance is confirmed clinically.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Anthracyclines are crucial anticancer drugs, primarily acting by inhibiting topoisomerase II (TOPO II).
  • Tumor cell resistance to anthracyclines is a significant clinical challenge, often involving multiple cellular mechanisms.
  • Understanding these resistance mechanisms is vital for developing more effective cancer therapies.

Purpose of the Study:

  • To review and summarize the known mechanisms of anthracycline resistance in tumor cells.
  • To differentiate between mechanisms observed in vitro and those clinically relevant.
  • To highlight the current understanding of factors contributing to treatment failure.

Main Methods:

  • Literature review of studies investigating anthracycline resistance.

Related Experiment Videos

  • Analysis of in vitro data on various resistance mechanisms.
  • Evaluation of clinical trial data on chemosensitizers and resistance.

    • Main Results:

    • Multidrug resistance (MDR) mediated by P-glycoprotein (PGP) is the most clinically established mechanism.
    • Other proposed mechanisms include non-PGP efflux pumps, altered drug distribution, glutathione transferase activity, TOPO II alterations, and enhanced DNA repair.
    • In vitro studies show evidence for these additional mechanisms, but clinical validation is largely lacking.

    Conclusions:

    • While multiple resistance mechanisms exist in vitro, only PGP-mediated MDR has been definitively linked to clinical anthracycline resistance.
    • Further research is needed to validate the clinical significance of other resistance pathways.
    • Targeting confirmed resistance mechanisms may improve therapeutic outcomes in cancer treatment.